Stocks · News reference
HDI Seguros Completes Integration of Sompo Life Insurance Portfolio onto insureMO Platform
HDI Seguros, a subsidiary of Talanx, has successfully migrated its life insurance portfolio acquired from Sompo onto the insureMO insurance middle office platform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Reported Earlier, Telix Reaffirms FY 2026 Revenue And Other Income Above $1B, Tracking Toward Upper End Of $950M-$970M Revenue Guidance, Revises R&D Spend Guidance To $240M-$260M
Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand
Telix Reports Third Quarter 2026 Financial Performance
Telix Pharmaceuticals reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, driven by strong demand for PSMA imaging products Gozellix and Illuccix. The company received FDA approval for Pixclara for glioma imaging and announced a transformational merger with Isotope Technologies Munich (ITM) for US$1.65 billion upfront, creating a vertically integrated radiopharmaceutical company with expanded isotope production capabilities. Telix reaffirmed FY 2026 revenue guidance exceeding US$1 billion.
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix Pharmaceuticals has partnered with Ekalia (a joint venture between IBA and Framatome) to establish dedicated U.S. production of astatine-211, a scarce alpha-emitting isotope for targeted alpha therapy. The collaboration will install IBA's alpha-beam cyclotron at Telix's RLS Radiopharmacies site near Philadelphia, securing long-term isotope access for Telix's pipeline including TLX102-Tx for glioblastoma, while also supporting third-party programs.
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate Astatine-211 production in the United States. The partnership will establish the first US production unit at RLS Trevose in Pennsylvania, with potential for further expansion. Telix will secure access to a portion of the production capacity to advance its alpha therapy pipeline.